Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2019 2
2020 4
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.
Ogura K, Somwar R, Hmeljak J, Magnan H, Benayed R, Momeni Boroujeni A, Bowman AS, Mattar MS, Khodos I, de Stanchina E, Jungbluth A, Asher M, Odintsov I, Hartono AB, LaQuaglia MP, Slotkin E, Pratilas CA, Lee SB, Spraggon L, Ladanyi M. Ogura K, et al. Among authors: odintsov i. Clin Cancer Res. 2021 Feb 15;27(4):1184-1194. doi: 10.1158/1078-0432.CCR-20-2585. Epub 2020 Nov 23. Clin Cancer Res. 2021. PMID: 33229458
A blast from the past: ROS1 on the brain.
Odintsov I, Somwar R, Davare MA. Odintsov I, et al. Oncotarget. 2019 Mar 1;10(18):1664-1666. doi: 10.18632/oncotarget.26752. eCollection 2019 Mar 1. Oncotarget. 2019. PMID: 30899438 Free PMC article. No abstract available.
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Hayashi T, Odintsov I, Smith RS, Ishizawa K, Liu AJW, Delasos L, Kurzatkowski C, Tai H, Gladstone E, Vojnic M, Kohsaka S, Suzawa K, Liu Z, Kunte S, Mattar MS, Khodos I, Davare MA, Drilon A, Cheng E, Stanchina E, Ladanyi M, Somwar R. Hayashi T, et al. Among authors: odintsov i. Dis Model Mech. 2020 Dec 14;14(2):dmm047779. doi: 10.1242/dmm.047779. Online ahead of print. Dis Model Mech. 2020. PMID: 33318047 Free PMC article.
Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.
Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi M. Suzawa K, et al. Among authors: odintsov i. JCO Precis Oncol. 2019;3:PO.19.00011. doi: 10.1200/PO.19.00011. Epub 2019 May 10. JCO Precis Oncol. 2019. PMID: 31157314 Free PMC article. No abstract available.
Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
Odintsov I, Mattar MS, Lui AJW, Offin M, Kurzatkowski C, Delasos L, Khodos I, Asher M, Daly RM, Rekhtman N, de Stanchina E, Ganji G, Ladanyi M, Somwar R. Odintsov I, et al. J Thorac Oncol. 2021 Jul;16(7):1149-1165. doi: 10.1016/j.jtho.2021.03.013. Epub 2021 Apr 8. J Thorac Oncol. 2021. PMID: 33839363
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions.
Odintsov I, Lui AJW, Sisso WJ, Gladstone E, Liu Z, Delasos L, Kurth RI, Sisso EM, Vojnic M, Khodos I, Mattar MS, de Stanchina E, Leland SM, Ladanyi M, Somwar R. Odintsov I, et al. Clin Cancer Res. 2021 Jun 1;27(11):3154-3166. doi: 10.1158/1078-0432.CCR-20-3605. Epub 2021 Apr 6. Clin Cancer Res. 2021. PMID: 33824166 Free article.